Cecilia Becattini Selected Research

Anticoagulants

7/2022	Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis.
5/2022	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
1/2022	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
1/2022	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
1/2022	ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis.
1/2022	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
1/2022	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function.
12/2021	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding.
11/2021	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
11/2021	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cecilia Becattini Research Topics

Disease

60	Hemorrhage 07/2022 - 12/2002
48	Venous Thromboembolism 07/2022 - 07/2003
34	Pulmonary Embolism 05/2022 - 12/2002
27	Neoplasms (Cancer) 05/2022 - 02/2008
23	Atrial Fibrillation 01/2021 - 01/2005
13	Thrombosis (Thrombus) 05/2022 - 01/2005
13	Stroke (Strokes) 11/2018 - 01/2005
10	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 02/2008
7	Ischemic Stroke 01/2020 - 03/2012
6	Renal Insufficiency (Renal Failure) 01/2022 - 09/2016
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 05/2022 - 05/2021
3	Thrombocytopenia (Thrombopenia) 05/2022 - 05/2019
3	COVID-19 02/2021 - 01/2021
3	Shock 11/2020 - 07/2007
3	Embolism (Embolus) 04/2019 - 03/2012
3	Right Ventricular Dysfunction 01/2018 - 11/2013
3	Myocardial Infarction 09/2014 - 03/2010
3	Clinical Deterioration 11/2013 - 10/2008
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022 - 01/2016
2	Infections 01/2022 - 07/2020
2	Inflammation (Inflammations) 01/2022 - 07/2020
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2020
2	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2021
2	Respiratory Insufficiency (Respiratory Failure) 01/2022 - 01/2021
2	Body Weight (Weight, Body) 05/2021 - 01/2020
2	Hematoma 01/2021 - 01/2020
2	Cerebral Hemorrhage 01/2020 - 01/2020
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020 - 01/2020
2	Embolic Stroke 01/2019 - 08/2015
2	Syncope (Fainting) 01/2018 - 01/2017
2	Overweight 05/2017 - 09/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2014 - 06/2007
2	Acute Coronary Syndrome 05/2008 - 01/2005
1	Severe Acute Respiratory Syndrome 05/2022
1	Infarction (Infarctions) 05/2022
1	Urogenital Neoplasms 05/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021
1	Melanoma (Melanoma, Malignant) 11/2021
1	Disease Progression 05/2021
1	Viremia 02/2021
1	Critical Illness (Critically Ill) 01/2021
1	Sepsis (Septicemia) 10/2020
1	Thrombotic Microangiopathies 07/2020
1	Hemophilia A (Haemophilia) 07/2020
1	Anemia 01/2020

Drug/Important Bio-Agent (IBA)

83	AnticoagulantsIBA 07/2022 - 07/2003
18	Vitamin K FDA Link 01/2022 - 01/2005
16	RivaroxabanIBA 01/2022 - 05/2010
14	apixabanIBA 05/2022 - 03/2012
12	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 05/2021 - 02/2008
11	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 12/2002
9	Dalteparin (Dalteparin Sodium)FDA Link 05/2022 - 09/2018
9	Dabigatran FDA Link 02/2020 - 05/2010
8	TroponinIBA 01/2021 - 07/2007
7	Pharmaceutical PreparationsIBA 10/2018 - 03/2012
7	Warfarin (Coumadin)FDA LinkGeneric 10/2018 - 02/2008
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 05/2012
5	Factor Xa InhibitorsIBA 01/2021 - 01/2016
4	CreatinineIBA 10/2021 - 09/2016
3	Enoxaparin (Lovenox)FDA LinkGeneric 01/2020 - 03/2012
3	fibrin fragment D (D-dimer)IBA 06/2017 - 02/2008
3	Tenecteplase FDA Link 03/2017 - 03/2010
3	AntithrombinsIBA 06/2012 - 01/2005
2	Hemoglobins (Hemoglobin)IBA 10/2021 - 11/2020
2	von Willebrand FactorIBA 07/2020 - 06/2007
2	edoxabanIBA 07/2020 - 01/2020
2	Factor Xa (Coagulation Factor Xa)IBA 06/2013 - 06/2012
2	Thrombin FDA Link 06/2013 - 06/2012
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2022
1	AntigensIBA 05/2022
1	Proteins (Proteins, Gene)FDA Link 05/2022
1	eltrombopag FDA Link 05/2022
1	VaccinesIBA 05/2022
1	Intravenous Immunoglobulins (IVIG)FDA Link 05/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	RNA (Ribonucleic Acid)IBA 02/2021
1	Viral RNAIBA 02/2021
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2021
1	Cytochrome P-450 CYP3AIBA 01/2021
1	Hemostatics (Antihemorrhagics)IBA 07/2020
1	Factor V (Coagulation Factor V)IBA 07/2020
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2020

Therapy/Procedure

29	Therapeutics 07/2022 - 07/2003
7	Length of Stay 01/2022 - 05/2008
5	Secondary Prevention 01/2020 - 02/2016
4	Thrombolytic Therapy 01/2020 - 04/2014
3	Duration of Therapy 07/2022 - 07/2003
2	Contraindications 01/2021 - 01/2020
2	Vena Cava Filters (Inferior Vena Cava Filter) 12/2016 - 09/2016
1	Catheters 05/2021
1	Noninvasive Ventilation 01/2021
1	Fluid Therapy (Oral Rehydration Therapy) 10/2020
1	Thrombectomy 01/2020
1	Drug Therapy (Chemotherapy) 01/2020